<DOC>
	<DOCNO>NCT00471432</DOCNO>
	<brief_summary>RATIONALE : OGX-011 may kill tumor cell block protein may cause tumor cell grow . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving OGX-011 together docetaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose OGX-011 give together docetaxel treat patient metastatic locally recurrent solid tumor .</brief_summary>
	<brief_title>OGX-011 Docetaxel Treating Patients With Metastatic Locally Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity recommend phase II dose OGX-011 administer docetaxel patient metastatic locally recurrent solid tumor . Secondary - Determine pharmacokinetic profile regimen patient . - Assess effect OGX-011 serum clusterin level clusterin expression peripheral blood mononuclear cell accessible tumor . - Assess objective response patient treat regimen . OUTLINE : This open-label , multicenter , dose-escalation study OGX-011 . Patients sequentially assign 1 2 treatment schedule . - Schedule A : Patients receive OGX-011 IV 2 hour day 1 , 3 , 5 , 8 , 15 , 22 , 29 , 36 course 1 weekly week 1-6 subsequent course . Patients also receive docetaxel IV 1 hour weekly week 1-5 . Treatment repeat every 6 week 4 course absence disease progression unacceptable toxicity . - Schedule B : Patients receive OGX-011 IV 2 hour day -7 , -5 , -3 , 1 , 8 , 15 course 1 day 1 , 8 , 15 subsequent course . Patients also receive docetaxel IV 1 hour day 1 . Treatment repeat every 3 week ( course 1 4 week duration ) 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos OGX-011 ( schedule ) recommend phase II dose ( RPTD ) determine . The RPTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients undergo serum collection periodically pharmacokinetic pharmacodynamic analysis . After completion study treatment , patient follow 4 week every 3 month thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor show overexpress clusterin , include limited , follow : Prostate cancer Renal cell carcinoma Nonsmall cell lung cancer Bladder cancer Breast cancer Ovarian cancer Metastatic locally recurrent disease Refractory standard curative therapy standard curative therapy exist Patients prostate cancer must hormone refractory ( i.e. , document evidence progression receive androgen ablative therapy ) Measurable nonmeasurable disease Measurable disease define measurable lesion ≥ 20 mm xray , physical exam , nonspiral CT scan ≥ 10 mm spiral CT scan No document CNS metastasis Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy ≥ 12 week Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin normal Creatinine ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN PT/INR PTT normal No uncontrolled pain No known bleed disorder No history serious allergic reaction taxane ( paclitaxel docetaxel ) No preexist peripheral neuropathy ≥ grade 2 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious illness medical condition would preclude study compliance , include follow : Active uncontrolled infection Significant cardiac dysfunction No significant neurological disorder would preclude give informed consent PRIOR CONCURRENT THERAPY : No prior strontium chloride Sr 89 No 2 prior chemotherapy regimen , include adjuvant neoadjuvant chemotherapy ( patient assign schedule B [ docetaxel every 3 week ] ) More 4 week since prior chemotherapy recover At least 4 week since prior antiandrogens More 4 week since prior externalbeam radiotherapy , except lowdose nonmyelosuppressive radiotherapy No prior radiotherapy ≥ 30 % marrowbearing area ( patient assign schedule B [ docetaxel every 3 week ] ) At least 28 day since prior new anticancer therapy At least 28 day since prior concurrent investigational agent No concurrent radiotherapy , except lowdose nonmyelosuppressive radiotherapy No concurrent cytotoxic therapy Concurrent luteinizing hormonereleasing hormone agonist allow ( already initiate patient prostate cancer ) No concurrent anticoagulant therapy ( i.e. , heparin , warfarin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>male breast cancer</keyword>
</DOC>